DiaMedica secures $30.1 million in private placement for clinical trials

DiaMedica Therapeutics Inc. (DMAC) has secured $30.1 million through a private placement of 8.6 million common shares at $3.50 each to fund its clinical development programs for preeclampsia, fetal growth restriction, and acute ischemic stroke, extending its operational runway by over two years. This capital infusion follows positive interim Phase 2 results for its DM199 drug candidate in preeclampsia, which demonstrated significant blood pressure reduction and improved uterine blood flow. Despite analysts not expecting profitability this year, the company maintains a strong balance sheet and has attracted bullish price targets, underscoring investor confidence in its pipeline and development trajectory.

Analysis

DiaMedica Therapeutics (DMAC) has substantially de-risked its medium-term operational outlook by securing $30.1 million in a private placement. The financing, priced at $3.50 per share with existing investors, extends the company's cash runway by over two years, providing ample capital to advance its lead drug candidate, DM199. This move is strategically timed, following positive interim Phase 2 data for DM199 in preeclampsia, which demonstrated statistically significant blood pressure reduction and a favorable safety profile. Financially, the company maintains a strong position for a clinical-stage entity, with more cash than debt and a current ratio of 8.02. While analysts do not project profitability this year and Q1 2025 revenue was zero, the company exceeded EPS forecasts at -$0.18 versus -$0.20. This financial discipline, coupled with strong clinical progress, has garnered significant analyst support, evidenced by price targets ranging from $11 to $14—a considerable premium to the placement price—and a recent target upgrade to $12 by H.C. Wainwright.

Key Decisions for Investors

• The successful private placement materially reduces financing risk and provides a clear runway to key clinical catalysts, strengthening the long-term investment thesis for risk-tolerant biotech investors.
• Investors should monitor upcoming clinical milestones, particularly the U.S. IND submission and the initiation of the Phase 2b study for DM199, as these will be primary drivers of future valuation.
• The private placement price of $3.50 per share serves as a strong valuation floor, and with analyst targets suggesting significant upside, the current market price may represent a compelling entry point.
• Despite positive developments, the company remains pre-revenue and speculative, so positions should be sized appropriately within a diversified portfolio, acknowledging the binary risk associated with clinical trial outcomes.